BAY-2402234 is a chemical compound under investigation for therapeutic applications in oncology, particularly for cancers associated with IDH1 and IDH2 gene mutations. It acts as a selective inhibitor of the mutant IDH enzymes, which helps reduce the production of toxic metabolites that promote cancer cell growth. Its medical use focuses on treating various cancers, such as acute myeloid leukemia (AML) and glioblastoma, which harbor IDH1/IDH2 mutations. Additionally, studies are exploring its potential in treating other cancers with these gene mutations.